Axitinib, sold under the brand name Inlyta, is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models[3] and has shown partial responses in clinical trials with renal cell carcinoma (RCC)[4] and several other tumour types.[5]
It was approved to treat renal cell carcinoma by the U.S. Food and Drug Administration after showing a modest increase in progression-free survival,[6] though there have been reports of fatal adverse effects.[7]
^Cite error: The named reference Inlyta FDA label was invoked but never defined (see the help page).
^ abcde"Inlyta (axitinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 25 January 2014.
^Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, et al. (April 2007). "AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging". Magnetic Resonance Imaging. 25 (3): 319–327. doi:10.1016/j.mri.2006.09.041. PMID 17371720.
^Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, et al. (June 2005). "AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)". Journal of Clinical Oncology ASCO Annual Meeting Proceedings. 23 (16S): 4509. Archived from the original on 2014-01-26.
^Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, et al. (August 2005). "Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results". Journal of Clinical Oncology. 23 (24): 5474–5483. doi:10.1200/JCO.2005.04.192. PMID 16027439.
^"FDA Approves Inlyta for Advanced Renal Cell Carcinoma". Drugs.com. January 27, 2012.
^Fauber J, Chu E (October 27, 2014). "The Slippery Slope: Is a Surrogate Endpoint Evidence of Efficacy?". MedPage Today.
Axitinib, sold under the brand name Inlyta, is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit...
This is a list of adverse effects of the anti-cancer drug axitinib, sorted by frequency of occurrence. Very common (>10% incidence) adverse effects include:...
BCR-ABL kinase translation and promoting its degradation by protease. Axitinib, a drug used to treat renal cell carcinoma, has been shown to be effective...
biological therapies such as everolimus, torisel, nexavar, sutent, and axitinib, the use of immunotherapy including interferon and interleukin-2. Immunotherapy...
chemotherapy. In May 2019, the FDA approved avelumab in combination with axitinib for the first-line treatment of people with advanced renal cell carcinoma...
progression of the cancer than pembrolizumab, axitinib and avelumab. In comparison to pembrolizumab and axitinib, it probably results in more death, but it...
treatment of advanced renal cell carcinoma (RCC) in adults in combination with axitinib. In June 2020, the US FDA approved a new indication for pembrolizumab as...
Global Information
(what is this?) (verify)